Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT00937079
Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients
Overview
The purpose of this study is to determine whether the investigators' new imaging modality (111In-exendin-4) has advantages in detecting insulinomas in comparison to conventional imaging.
Sponsor
University Hospital, Basel, Switzerland
Contacts
Damian Wild, MD (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT00937079Drug / Compound
exendin-4
Isotope(s):
INDIUM-111
Radioisotope: In-111
Theranostic Role: SPECT Imaging
T1/2 (Half-Life): 2.8 Days
Decay Mode: ELECTRON CAPTURE, GAMMA
Energy: 173 keV, 247 keV
Range: N/A
Decay Daughters: Cd111 (Stable)
Status: FDA Approvals: ONCOSCINT® (1992), OCTREOSCAN® (1994)
Target(s):
- Glucagon-Like Peptide-1 Receptor (GLP1R)
Ligand Class: Peptides
Chelator: DTPA
Linker: Ahx
Eligibility
Inclusion
- Biochemically proven endogenous hyperinsulinism confirmed by hypoglycaemia with neuroglycopenic symptoms, inadequately high serum insulin and C-peptide concentrations and negative sulfonylurea screening as well as low serum beta-hydroxybutyrate concentrations
Exclusion
- Allergy to exendin-4 (Byetta®)
- Renal insufficiency (creatinine \> 140 micromol/l)
Share your feedback
Help us improve your experience